作为第三代表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs),奥希替尼(AZD9291)已被批准用于一线治疗EGFR外显子19缺失或外显子21 L858R突变的转移性非小细胞肺癌(non-small cell lung cancer, NSCLC)患者。. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.